Literature DB >> 10220502

Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

K L Madsen1, J S Doyle, L D Jewell, M M Tavernini, R N Fedorak.   

Abstract

BACKGROUND & AIMS: Intestinal luminal microflora, or their products, are likely an important initiating factor in the pathogenesis of inflammatory bowel disease. The aim of this study was to determine the role of colonic aerobic luminal bacteria and Lactobacillus species in the development of colitis in interleukin (IL)-10 gene-deficient mice.
METHODS: Intestine from 2-16-week-old mice was scored histologically and cultured for bacteria. Lactobacillus sp. repopulation of the colonic lumen was achieved via daily rectal delivery of Lactobacillus reuteri or oral lactulose therapy.
RESULTS: At 2 weeks of age, IL-10 gene-deficient mice showed no colonic injury but did display abnormal colonic bacterial colonization with increased colonic mucosal aerobic adherent and translocated bacteria in conjunction with reduced Lactobacillus sp. levels. In association with the abnormal colonic bacterial colonization, colitis developed by 4 weeks of age. Restoring Lactobacillus sp. to normal levels reduced levels of colonic mucosal adherent and translocated bacteria and attenuated the development of the colitis.
CONCLUSIONS: In the neonatal period, IL-10 gene-deficient mice have decreased levels of colonic Lactobacillus sp. and an increase in colonic mucosal adherent and translocated bacteria. Normalizing Lactobacillus sp. levels reduced colonic mucosal adherent and translocated bacteria and prevented colitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220502     DOI: 10.1016/s0016-5085(99)70013-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  184 in total

Review 1.  The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease.

Authors:  W Strober; K Nakamura; A Kitani
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 2.  Probiotics in inflamatory bowel disease.

Authors:  F Shanahan
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 3.  Bacteria as the cause of ulcerative colitis.

Authors:  M Campieri; P Gionchetti
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

4.  Probiotics in the Treatment of Diarrheal Diseases.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

Review 5.  Probiotics and immune response.

Authors:  Stephanie Blum; Dirk Haller; Andrea Pfeifer; Eduardo J Schiffrin
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

Review 6.  Probiotics in the management and prevention of atopy.

Authors:  John Bienenstock; Ryan E Wiley; G Scott Neigh; Susan Waserman; Paul Keith
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

7.  Functional foods and probiotics: time for gastroenterologists to embrace the concept.

Authors:  F Shanahan; J McCarthy
Journal:  Curr Gastroenterol Rep       Date:  2000-10

Review 8.  Probiotics and inflammatory bowel disease.

Authors:  Daisy Jonkers; Reinhold Stockbrügger
Journal:  J R Soc Med       Date:  2003-04       Impact factor: 5.344

9.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

10.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.